P00797 (RENI_HUMAN) Homo sapiens (Human)
Renin UniProtKBInterProSTRINGInteractive Modelling
It is possible new templates exist for this target since these models were created.
Available Structures
91 Experimental Structures
Description | PDB ID | Oligo-state | Range | Ligands | ||
---|---|---|---|---|---|---|
Crystal structure of human prorenin |
Heteromer | 1×NAG; | ||||
Assess | ||||||
Crystal structure of the complex of human angiotensinogen and renin at 2.55 Angstrom |
Heteromer P01019; | 1×NAG; 1×NAG; 10×SO4; 1×GOL; | ||||
Assess | ||||||
Crystal structure of human angiotensinogen complexed with renin |
Heteromer P01019; | |||||
Assess | ||||||
Crystal Structure of Human Renin Complexed with Inhibitor | homo-6-mer | 3×7IG; | ||||
Assess | ||||||
Crystal Structure of Human Renin Complexed with Inhibitor | homo-6-mer | 6×LIX; 3×CIT; | ||||
Assess | ||||||
Crystal Structure of Human Renin Complexed with Inhibitors | homo-6-mer | 6×LIY; | ||||
Assess | ||||||
Crystal Structure of Renin with Inhibitor 3 | homo-6-mer | 6×C47; | ||||
Assess | ||||||
Crystal structure at 2.6A of human prorenin | homo-2-mer | 2×NAG; 10×SO4; | ||||
Assess | ||||||
HIGH RESOLUTION CRYSTAL STRUCTURES OF RECOMBINANT HUMAN RENIN IN COMPLEX WITH POLYHYDROXYMONOAMIDE … | homo-2-mer | 2×NAG; 2×03D; | ||||
Assess | ||||||
Optimization of Orally Bioavailable Alkyl Amine Renin Inhibitors | homo-2-mer | 1×NAG; 4×22X; 1×NAG; | ||||
Assess | ||||||
Design and optimization of new piperidines as renin inhibitors | homo-2-mer | 1×NAG; 1×LPO; | ||||
Assess | ||||||
Design and optimization of new piperidines as renin inhibitors | homo-2-mer | 1×NAG; 1×LPQ; | ||||
Assess | ||||||
Design and optimisation of new piperidines as renin inhibitors | homo-2-mer | 1×NAG; 1×LPN; | ||||
Assess | ||||||
CRYSTALLOGRAPHIC STUDIES ON THE BINDING MODES OF P2-P3 BUTANEDIAMIDE RENIN INHIBITORS | homo-2-mer | 2×0IU; | ||||
Assess | ||||||
CRYSTALLOGRAPHIC STUDIES ON THE BINDING MODES OF P2-P3 BUTANEDIAMIDE RENIN INHIBITORS | homo-2-mer | 2×0QB; | ||||
Assess | ||||||
Crystal Structure of Renin with Inhibitor 8 | homo-2-mer | 2×C39; | ||||
Assess | ||||||
THE CRYSTAL STRUCTURE OF RECOMBINANT GLYCOSYLATED HUMAN RENIN ALONE AND IN COMPLEX WITH A TRANSITIO… | homo-2-mer | 2×NAG; 2×C60; | ||||
Assess | ||||||
Human renin/PF02342674 complex | homo-2-mer | 2×UA4; | ||||
Assess | ||||||
Design and Preparation of Potent, Non-Peptidic, Bioavailable Renin Inhibitors | monomer | 1×A7T; 2×NAG; | ||||
Assess | ||||||
Structure-based design of 4-hydroxy-3,5-substituted piperidines as direct renin inhibitors | monomer | 1×DMS; 1×NAG; 1×PO4; 1×2Y9; | ||||
Assess | ||||||
Human renin in complex with compound2 | monomer | 1×NAG; 1×UNL; | ||||
Assess | ||||||
Structure-Based Optimization of Potent 4- and 6-Azaindole-3-Carboxamides as Renin Inhibitors | monomer | 1×NAG; 3×GOL; 2×S53; | ||||
Assess | ||||||
Crystal Structure of Renin with Inhibitor 10 (Aliskiren) | monomer | 1×NAG; 1×C41; | ||||
Assess | ||||||
Human renin in complex with compound1 | monomer | 1×NAG; 1×UNL; | ||||
Assess | ||||||
Crystal structure of renin in complex with NVP-AMQ838 (compound 5) | monomer | 1×NAG; 1×0LR; | ||||
Assess | ||||||
Crystal structure of renin in complex with NVP-BCH965 (compound 9) | monomer | 1×NAG; 1×0MJ; 2×SO4; | ||||
Assess | ||||||
Crystal structure of renin in complex with PKF909-724 (compound 3) | monomer | 1×NAG; 2×0LU; 1×SO4; | ||||
Assess | ||||||
Crystal structure of renin in complex with NVP-AYL747 (compound 5) | monomer | 1×NAG; 1×0M3; 2×SO4; | ||||
Assess | ||||||
Human renin in complex with compound 5 | monomer | 1×NAG; 1×HHE; | ||||
Assess | ||||||
Human renin in complex with compound3 | monomer | 1×NAG; 1×UNL; | ||||
Assess | ||||||
Human renin in complex with inhibitor 7 | monomer | 1×NAG; 1×VYE; | ||||
Assess | ||||||
Crystal structure of renin in complex with NVP-BBV031 (compound 6) | monomer | 1×NAG; 1×0ME; 1×SO4; | ||||
Assess | ||||||
Human renin in complex with compound 18 | monomer | 1×NAG; 1×R32; | ||||
Assess | ||||||
Human renin in complex with inhibitor 9 | monomer | 1×NAG; 1×VYF; | ||||
Assess | ||||||
Human renin in complex with inhibitor 6 | monomer | 1×NAG; 1×VYD; | ||||
Assess | ||||||
Human renin in complex with compound 8 | monomer | 1×NAG; 1×R31; | ||||
Assess | ||||||
Structure-based design of a new series of N-piperidin-3-ylpyrimidine-5-carboxamides as renin inhibi… | monomer | 1×NAG; 1×74U; 1×PEG; | ||||
Assess | ||||||
Renin in complex with (S)-1-(3-fluoro-5-(((S)-1-phenylethyl)carbamoyl)benzyl)-4-isopropyl-4-methyl-… | monomer | 1×NAG; 1×43T; | ||||
Assess | ||||||
Structure-based design of a new series of N-piperidin-3-ylpyrimidine-5-carboxamides as renin inhibi… | monomer | 1×NAG; 1×74V; 1×PGE; 2×DMS; | ||||
Assess | ||||||
Renin in complex with (4S)-4-isopropyl-4-methyl-6-oxo-1-(3-(2-oxo-4-phenylpyrrolidin-1-yl)benzyl)te… | monomer | 1×NAG; 1×70Y; | ||||
Assess | ||||||
Renin in complex with (S)-1-(3-(benzylcarbamoyl)benzyl)-4-isopropyl-4-methyl-6-oxotetrahydropyrimid… | monomer | 1×NAG; 1×70X; | ||||
Assess | ||||||
RENIN IN COMPLEXED WITH 4-methoxy-3-(3-methoxypropoxy)-N-{[(3S,4S)-4-{[(4-methylphenyl)sulfonyl]ami… | monomer | 1×NAG; 1×3ZK; 1×SO4; | ||||
Assess | ||||||
Crystal structure of renin in complex with NVP-AYZ832 (compound 6a) | monomer | 1×NAG; 2×0LS; 1×SO4; | ||||
Assess | ||||||
RENIN IN COMPLEXED WITH (3S,4S)-4-({[4-methoxy-3-(3-methoxypropoxy)benzoyl](propan-2-yl)amino}methy… | monomer | 1×NAG; 1×3ZN; 1×SO4; | ||||
Assess | ||||||
Novel Approach of Fragment-Based Lead Discovery applied to Renin Inhibitors | monomer | 1×NAG; 1×PG6; 2×DMS; | ||||
Assess | ||||||
RENIN IN COMPLEXED WITH N-({(3S,4S)-4-[(benzylsulfonyl)amino]pyrrolidin-3-yl}methyl)-4-methoxy-3-(3… | monomer | 1×NAG; 1×3ZJ; 1×SO4; | ||||
Assess | ||||||
Crystal structure of renin in complex with NVP-BGQ311 (compound 12) | monomer | 1×NAG; 1×0N0; 1×SO4; | ||||
Assess | ||||||
Crystal structure of renin in complex with NVP-BCA079 (compound 12a) | monomer | 1×NAG; 1×0LT; 1×SO4; | ||||
Assess | ||||||
Crystal structure of renin in complex with GP055321 (compound 4) | monomer | 1×NAG; 1×0M2; | ||||
Assess | ||||||
Crystal structure of renin in complex with compound4 | monomer | 1×NAG; 1×2XF; 1×DMS; 1×SO4; | ||||
Assess | ||||||
New Classes of Potent and Bioavailable Human Renin Inhibitors | monomer | 1×BFX; 1×FMT; 1×NAG; | ||||
Assess | ||||||
Design and Preparation of Potent, Non-Peptidic, Bioavailable Renin Inhibitors | monomer | 1×DMS; 1×NAG; 1×A6T; | ||||
Assess | ||||||
Design and Preparation of Potent, Non-Peptidic, Bioavailable Renin Inhibitors | monomer | 1×A5T; 1×DMS; 1×NAG; | ||||
Assess | ||||||
Crystal structure of human renin complexed with a novel inhibitor | monomer | 1×NAG; 1×72X; 4×GOL; 1×CL; | ||||
Assess | ||||||
Potent macrocyclic renin inhibitors | monomer | 3×ACT; 2×NA; 1×3OX; | ||||
Assess | ||||||
Discovery of TAK-272: A Novel, Potent and Orally Active Renin In-hibitor | monomer | 1×NAG; 1×6VU; 1×PGE; 3×PEG; 8×DMS; | ||||
Assess | ||||||
Clinically Useful Alkyl Amine Renin Inhibitors | monomer | 1×NAG; 4×CL; 1×RX6; | ||||
Assess | ||||||
Clinically Useful Alkyl Amine Renin Inhibitors | monomer | 1×NAG; 4×CL; 1×RX5; | ||||
Assess | ||||||
Optimization of 3,5-Disubstitued Piperidine: Discovery of Non-Peptide mimetics as an Orally Active … | monomer | 1×NAG; 1×7EK; 1×PGE; 1×PEG; 3×DMS; | ||||
Assess | ||||||
Human renin in complex with remikiren | monomer | 1×REM; 1×DMS; | ||||
Assess | ||||||
Structure-based design of a new series of N-piperidin-3-ylpyrimidine-5-carboxamides as renin inhibi… | monomer | 1×NAG; 1×74Z; 6×DMS; 1×PEG; 1×1PE; | ||||
Assess | ||||||
Discovery of TAK-272: A Novel, Potent and Orally Active Renin In-hibitor | monomer | 1×NAG; 1×6VS; 8×DMS; 2×PEG; | ||||
Assess | ||||||
STRUCTURE OF RECOMBINANT HUMAN RENIN, A TARGET FOR CARDIOVASCULAR-ACTIVE DRUGS, AT 2.5 ANGSTROMS RE… | monomer | 1×NAG; | ||||
Assess | ||||||
Crystal Structure Analysis of Renin-indole-piperazin inhibitor complexes | monomer | 1×NAG; 1×SSR; | ||||
Assess | ||||||
Alkyl Amine Renin Inhibitors: Filling S1 from S3 | monomer | 1×NAG; 1×RX0; 2×GOL; | ||||
Assess | ||||||
Crystal Structure of Human Renin in Complex with a biphenylpipderidinylcarbinol | monomer | 1×NAG; 2×90D; | ||||
Assess | ||||||
Optimization of 3,5-Disubstitued Piperidine: Discovery of Non-Peptide mimetics as an Orally Active … | monomer | 1×NAG; 1×7EJ; 3×DMS; | ||||
Assess | ||||||
Crystal Structure Analysis of Renin-indole-piperazine inhibitor complexes | monomer | 1×NAG; 1×S51; | ||||
Assess | ||||||
Structure-based design of a new series of N-piperidin-3-ylpyrimidine-5-carboxamides as renin inhibi… | monomer | 1×NAG; 1×74Y; 3×PEG; | ||||
Assess | ||||||
Crystal Structure of Human Renin in Complex with a biphenylpipderidinylcarbinol | monomer | 1×NAG; 1×9G7; 1×SO4; | ||||
Assess | ||||||
Crystal Structure Analysis of Renin-indole-piperazin inhibitor complexes | monomer | 1×NAG; 1×S52; | ||||
Assess | ||||||
Crystal Structure of Renin with Inhibitor 9 | monomer | 1×C61; | ||||
Assess | ||||||
Crystal Structure of Renin with Inhibitor 6 | monomer | 1×C80; | ||||
Assess | ||||||
Crystal Structure of Human Renin in Complex with a biphenylpipderidinylcarbinol | monomer | 1×NAG; 1×SO4; 2×9JD; | ||||
Assess | ||||||
Discovery of TAK-272: A Novel, Potent and Orally Active Renin In-hibitor | monomer | 1×NAG; 1×6VR; | ||||
Assess | ||||||
Crystal Structure of Renin with Inhibitor 7 | monomer | 1×C40; | ||||
Assess | ||||||
X-RAY ANALYSES OF PEPTIDE INHIBITOR COMPLEXES DEFINE THE STRUCTURAL BASIS OF SPECIFICITY FOR HUMAN … | monomer | |||||
Assess | ||||||
crystal structure of renin-pf00257567 complex | monomer | 1×RPF; | ||||
Assess | ||||||
Ketopiperazine-Based Renin Inhibitors: Optimization of the "C" Ring | monomer | 1×7IG; | ||||
Assess | ||||||
Ketopiperazine-Based Renin Inhibitors: Optimization of the "C" Ring | monomer | |||||
Assess | ||||||
Ketopiperazine-Based Renin Inhibitors: Optimization of the "C" Ring | monomer | 1×L1B; | ||||
Assess | ||||||
Ketopiperazine-Based Renin Inhibitors: Optimization of the C ring | monomer | |||||
Assess | ||||||
crystal structure of Renin-PF00074777 complex | monomer | |||||
Assess | ||||||
Ketopiperazine-Based Renin Inhibitors: Optimization of the C Ring | monomer | 1×L1A; | ||||
Assess | ||||||
Ketopiperazine-Based Renin Inhibitors: Optimization of the C Ring | monomer | 1×NAG; 1×3IG; | ||||
Assess | ||||||
Ketopiperazine-Based Renin Inhibitors: Optimization of the "C" Ring | monomer | 1×NAG; 1×5IG; | ||||
Assess | ||||||
Ketopiperazine-Based Renin Inhibitors: Optimization of the "C" Ring | monomer | 1×NAG; 1×6IG; | ||||
Assess | ||||||
Ketopiperazine-Based Renin Inhibitors: Optimization of the C Ring | monomer | 1×NAG; 1×4IG; | ||||
Assess | ||||||
Ketopiperazine-Based Renin Inhibitors: Optimization of the "C" Ring | monomer | 1×NAG; 1×2IG; | ||||
Assess | ||||||
Ketopiperazine-based renin inhibitors: Optimization of the "C" ring | monomer | 1×NAG; 1×1IG; | ||||
Assess | ||||||
Ketopiperazine-Based Renin Inhibitors: Optimization of the "C" Ring | monomer | 1×4LG; | ||||
Assess |
2 SWISS-MODEL models
Template | Oligo-state | QMEANDisCo | Range | Ligands | Trg-Tpl Seq id (%) | |
---|---|---|---|---|---|---|
2x0b.1.A | monomer | 0.90 | 100.00 | |||
Assess | ||||||
4amt.1.A | monomer | 0.78 | 100.00 | |||
Assess |
2 SWISS-MODEL models built on isoform sequence
Template | Isoform | Oligo-state | QMEANDisCo | Range | Ligands | Trg-Tpl Seq id (%) |
---|---|---|---|---|---|---|
Isoform 2 | 2x0b.1.A | monomer | 0.90 | 99.47 | ||
Assess | ||||||
Isoform 2 | 4amt.1.A | monomer | 0.78 | 100.00 | ||
Assess |